GVK BIO Announces the Appointment of Axel Schleyer, Ph.D. as Chief Executive Officer, Aragen Bioscience, Inc.

HYDERABAD, India & MORGAN HILL, Calif.–(BUSINESS WIRE)–lt;a href="https://twitter.com/hashtag/Antibodydiscovery?src=hash" target="_blank"gt;#Antibodydiscoverylt;/agt;–GVK BIO is pleased to announce the appointment of Dr. Axel Schleyer as
Chief Executive Officer, Aragen Bioscience Inc. Aragen, a wholly-owned
subsidiary of GVK BIO, is a leading Contract Research Organization
focused on accelerating biologicals product development with an
integrated offering that includes antibody discovery and humanization,
stable cell line development, recombinant protein production and
purification, and differentiated diseases models.

“I am delighted to welcome Dr. Axel Schleyer as the Chief Executive
Officer, Aragen Bioscience. Axel brings a wealth of business,
technology, regulatory and strategic acumen, and has an impressive
record of consistently delivering high performance with a customer
focus,” said Manni Kantipudi, Chairman, Aragen Bioscience, Director &
CEO, GVK BIO. “We are confident that under his leadership, Aragen
will expand its offering, and build on its growth over the past few
years.”

“I am excited to lead Aragen Bioscience and look forward to assisting
our customers in developing solutions that impact human health. With
large molecules contributing to approximately 40% of the global
portfolio, interest in Biologics research continues to grow rapidly,” added
Dr. Axel Schleyer. “With its strong scientific leadership, ‘customer
first’ culture, state-of-the-art infrastructure, and an ideal location
in the Bay area, Aragen is well positioned to benefit from market
trends.”

A seasoned Pharmaceutical and Biotechnology professional, Dr. Schleyer
has over two decades of industry experience, building and leading
high-performance teams, spearheading global business initiatives, and
formulating business strategies resulting in successful outcomes. Prior
to joining Aragen, Dr. Schleyer served as Senior Vice President, AGC
Biologics and has held roles of increasing responsibilities at Lonza,
Siegfried, Baxter Healthcare and Boehringer Ingelheim.

Dr. Schleyer has completed his postdoctoral studies at The Scripps
Research Institute, La Jolla, CA and at Carlsberg Institute, Copenhagen,
Denmark. He completed his Ph.D. in Chemistry from the University of
Hamburg, and holds a Master of Business Administration degree from
California State University, San Marcos.

About GVK BIO

GVK BIO, a leading Contract Research & Development Organization
servicing the global Biopharma industry, is headquartered in Hyderabad,
India with operations in five sites including California, USA.
Established in 2001, GVK BIO has over 18 years of experience across the
Research and Development value chain with a focus on speed and quality
while ensuring safety and compliance. GVK BIO’s team of over 2100 highly
qualified scientists, backed by a no-conflict business model,
well-defined and scalable processes, modern facilities, and a strong
customer-centric partnering approach, focus on bringing its customers’
products to market. www.gvkbio.com

About Aragen Bioscience, Inc.

Aragen Bioscience, Inc., a wholly owned subsidiary of GVK BIO, is a
leading contract research organization based in the San Francisco Bay
Area. Aragen Bioscience offers a diverse set of In Vitro and In
Vivo services for the discovery, characterization, activity
assessment and early development of biologic and diagnostic products. www.aragenbio.com

Contacts

Dorothy Paul
[email protected]
Phone:
+91 9908130236